scholarly journals Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant hodgkin lymphoma: Long-term outcomes from a 30-year experience

2015 ◽  
Vol 90 (6) ◽  
pp. E103-E110 ◽  
Author(s):  
Toby A. Eyre ◽  
Kevin Gatter ◽  
Graham P. Collins ◽  
Georgina W. Hall ◽  
Caroline Watson ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
High Grade ◽  
Long Term Outcomes ◽  
High Grade Transformation

scholarly journals MNGI-14. LONG-TERM OUTCOMES FOLLOWING SURGERY AND/OR RADIATION THERAPY IN PATIENTS WITH HIGH-GRADE MENINGIOMA

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi135-vi135
Author(s):  
Olayode Babatunde ◽  
Collin Kent ◽  
Yvonne Mowery ◽  
Frances McSherry ◽  
James E Herndon ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
High Grade ◽  
Long Term Outcomes

Activity of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis Predicts Poorer Clinical Outcomes

2020 ◽  
Vol 26 (12) ◽  
pp. 1901-1908 ◽  
Author(s):  
Matthew Peverelle ◽  
Sarang Paleri ◽  
Jed Hughes ◽  
Peter De Cruz ◽  
Paul J Gow
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Liver Transplantation ◽  
Bowel Disease ◽  
Sclerosing Cholangitis ◽  
High Grade ◽  
Long Term Outcomes ◽  
Inflammatory Bowel ◽  
The Impact

Abstract Background The impact of inflammatory bowel disease (IBD) activity on long-term outcomes after liver transplantation (LT) for primary sclerosing cholangitis (PSC) is unknown. We examined the impact of post-LT IBD activity on clinically significant outcomes. Methods One hundred twelve patients undergoing LT for PSC from 2 centers were studied for a median of 7 years. Patients were divided into 3 groups according to their IBD activity after LT: no IBD, mild IBD, and moderate to severe IBD. Patients were classified as having moderate to severe IBD if they met at least 1 of 3 criteria: (i) Mayo 2 or 3 colitis or Simple Endoscopic Score–Crohn’s Disease ≥7 on endoscopy; (ii) acute flare of IBD necessitating steroid rescue therapy; or (iii) post-LT colectomy for medically refractory IBD. Results Moderate to severe IBD at any time post-transplant was associated with a higher risk of Clostridium difficile infection (27% vs 8% mild IBD vs 8% no IBD; P = 0.02), colorectal cancer/high-grade dysplasia (21% vs 3% both groups; P = 0.004), post-LT colectomy (33% vs 3% vs 0%) and rPSC (64% vs 18% vs 20%; P < 0.001). Multivariate analysis revealed that moderate to severe IBD increased the risk of both rPSC (relative risk [RR], 8.80; 95% confidence interval [CI], 2.81–27.59; P < 0.001) and colorectal cancer/high-grade dysplasia (RR, 10.45; 95% CI, 3.55–22.74; P < 0.001). Conclusions Moderate to severe IBD at any time post-LT is associated with a higher risk of rPSC and colorectal neoplasia compared with mild IBD and no IBD. Patients with no IBD and mild IBD have similar post-LT outcomes. Future prospective studies are needed to determine if more intensive treatment of moderate to severe IBD improves long-term outcomes in patients undergoing LT for PSC.

scholarly journals Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma

2012 ◽  
Vol 159 (3) ◽  
pp. 329-339 ◽  
Author(s):  
Ann Y. Minn ◽  
Elyn Riedel ◽  
Jerry Halpern ◽  
Laura J. Johnston ◽  
Sandra J. Horning ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
High Dose ◽  
Long Term Outcomes ◽  
High Dose Therapy ◽  
Dose Therapy ◽  
Haematopoietic Cell

scholarly journals Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma

2017 ◽  
Vol 178 (2) ◽  
pp. 250-256 ◽  
Author(s):  
Peter Martin ◽  
Zhengming Chen ◽  
Bruce D. Cheson ◽  
Katherine S. Robinson ◽  
Michael Williams ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hodgkin Lymphoma ◽  
Secondary Malignancies ◽  
Long Term Outcomes ◽  
Non Hodgkin Lymphoma ◽  
Previously Treated ◽  
Stem Cell Collection

Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 536-536 ◽  
Author(s):  
Kanti R. Rai ◽  
Bercedis L. Peterson ◽  
Frederick R. Appelbaum ◽  
Martin S. Tallman ◽  
Andrew Belch ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Initial Treatment ◽  
Conflicts Of Interest ◽  
High Morbidity ◽  
Second Malignancies ◽  
Long Term Outcomes ◽  
Term Survival ◽  
Prolymphocytic Leukemia

Abstract Abstract 536 Long-term outcomes following novel therapies for CLL have rarely been reported. Between 10/90 and 12/94, 509 eligible, untreated patients (pts) with symptomatic CLL were enrolled by 4 cooperative groups onto study C9011; 179 were randomized to F, 193 to C, and 137 to F+C. After slightly more than 5 years median follow up, with the time of last follow-up in June 1999, we reported in 2000 (NEJM 343:1750) that F provided significantly higher response rates and longer remission duration and progression-free survival (PFS) than C (p<0.001 for all 3 endpoints). The combination arm with F+C was stopped early because of high morbidity and mortality. There was no difference in overall survival (OS) among the 3 groups. Nearly 10 years have now elapsed since this report. Therefore, with the time of last follow-up in January 2009, we analyzed the long term outcomes of pts enrolled on the study. PFS was defined as the time between randomization and the occurrence of progressive disease or death due to any cause. Results: Of the 509 pts, 85% have now died; among pts on the F and C arms, 92% have progressed. We found that F treatment resulted in significantly longer PFS than did C (p < 0.001), with notable differences in PFS at 2, 3, and 4 years (Table). While the F and C arms had the same OS during the initial 5 years following randomization, our current analysis with longer follow-up shows that pts treated on the F arm had better survival than did those on the C arm during the ensuing years (Figure). The p-values for this difference are 0.04 (unadjusted for covariates) and 0.07 (covariate-adjusted). The emergence of improved survival following initial F treatment, appearing only after 5-6 years, is an unexpected and noteworthy finding. Reporting second malignancies was required on this study. There were 27 epithelial cancers reported (9 on F, 11 on C, 7 on F+C), involving colon, lung, breast, prostate, pancreas, liver, bladder and skin (6 squamous, 2 melanoma). Seven therapy-related myeloid neoplasms (t-MN) were reported; 6 were on F+C; 1 on F. Richter's transformation to non-Hodgkin lymphoma was reported in 34 pts; prolymphocytic leukemia occurred in 10; Hodgkin lymphoma in 6; myeloma in 2; hairy cell leukemia in 1. These cases were distributed with 18 on F, 18 on C, and 17 on F+C. Thus, the overall incidence of second malignancies reported was 17%. Conclusion: Initial treatment with F provides better long-term outcomes than initial treatment with C. Second malignancies are common, but the overall incidence is not increased on the F-containing treatment arms except for t-MN. Disclosures: No relevant conflicts of interest to declare.

scholarly journals EP-1209: Long-term outcomes following conventionally fractionated stereotactic boost for high-grade glioma

2018 ◽  
Vol 127 ◽  
pp. S673 ◽  
Author(s):  
M. Repka ◽  
S. Lei ◽  
L. Campbell ◽  
S. Suy ◽  
J. Voyadzis ◽  
...  
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Long Term Outcomes ◽  
Conventionally Fractionated
Sign in / Sign up

Export Citation Format

Share Document